Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer - PubMed
4 hours ago
- #immunotherapy
- #biomarkers
- #colorectal cancer
- The METIMMOX trial evaluated oxaliplatin-based chemotherapy alternating with nivolumab for metastatic microsatellite-stable colorectal cancer.
- Patients with TMB ≥9 or BRAF-V600E mutation had a median PFS of 19.8 months, significantly longer than others.
- Combining TMB ≥9 or BRAF-V600E with normal C-reactive protein levels resulted in a median PFS of 35.0 months.
- TMB, BRAF status, and systemic inflammation are suggested as biomarkers for predicting response to immune checkpoint inhibitors.
- The trial was approved by ethical committees and conducted in accordance with Good Clinical Practice and the Declaration of Helsinki.